The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
If you feel stressed out, consider techniques such as yoga, therapy, meditation, deep breathing, or journaling
After obtaining count data for the IMSA cohort, the IMSA and SARP count data were processed together
doi:10.1016/j.peptides.2011.03.014 Cheng J, Wu TJ, Butler B, Cheng K
Bottom line: The pattern across thousands of reviews is consistent: people try several trackers and stay where the whole journey lives in one place
Coaching ensures patients stay active, motivated, and accountable